<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493125</url>
  </required_header>
  <id_info>
    <org_study_id>3-2020-0175</org_study_id>
    <nct_id>NCT04493125</nct_id>
  </id_info>
  <brief_title>The Effect of Mosapride Citrate on Gastrointestinal Motility After Gastrectomy: Prospective, Double Blind Placebo-controlled Study</brief_title>
  <official_title>The Effect of Mosapride Citrate on Gastrointestinal Motility After Gastrectomy:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an&#xD;
      agent to increase intestinal motility. Mosapride citrate has been demonstrated in in vitro&#xD;
      and in vivo studies to increase both gastric and colon motility. In a case-control study of&#xD;
      patients undergoing colonectomy, mosapride citrate was found to significantly reduce gas&#xD;
      passing and defecation time.&#xD;
&#xD;
      Recently, a study reported that mosapride citrate acts on the Î±7nACh receptor and,&#xD;
      consequently, suppresses the inflammatory response of macrophages, thereby suppressing the&#xD;
      mechanism that induces paralysis after surgery.&#xD;
&#xD;
      To date, this study is intended to analyze whether mosapride citrate significantly affects&#xD;
      the improvement of bowel movement after surgery after gastrectomy.&quot;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 27, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of radiopaque markers transferred to the large intestine 3 days after surgery</measure>
    <time_frame>3 Days after surgery</time_frame>
    <description>Intestinal motility after gastrectomy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>Mosapride group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride citrate</intervention_name>
    <description>Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.</description>
    <arm_group_label>Mosapride group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with gastric cancer pathologically before surgery&#xD;
&#xD;
          2. Patients who underwent surgical resection (R0 resection)&#xD;
&#xD;
          3. Patients with an ASA score of 3 or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients over 80 years old&#xD;
&#xD;
          2. When there are multiple or peritoneal metastases&#xD;
&#xD;
          3. Intestinal obstruction before surgery&#xD;
&#xD;
          4. When chemotherapy was performed before surgery&#xD;
&#xD;
          5. When cancer other than stomach cancer is diagnosed&#xD;
&#xD;
          6. If you have a long history of major intra-abdominal surgery or a history of abdominal&#xD;
             radiotherapy&#xD;
&#xD;
          7. In case of liver failure or kidney failure&#xD;
&#xD;
          8. When it is judged that uncontrolled diabetes may affect intestinal function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>In Gyu Kwon</investigator_full_name>
    <investigator_title>Assistnat Professor</investigator_title>
  </responsible_party>
  <keyword>Gastrectomy, Intestinal motility, Mosapride, Adhesion, Ileus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

